Client success stories
Changing the lives of patients by working closely with top Pharma and CDMOs to transform their manufacturing operations and accelerate their time-to-market and product quality.
Helping Leading Biotech Company Use AI to Improve Yield
A leading biotech company reached out to Aizon to identify how artificial intelligence (AI) could tackle these challenges and be used to further optimize yield. Using Aizon’s Fast Forward and Blueprint services, the integrated team was able to identify real opportunities to leverage AI in their specific environment and build a roadmap to achieve those goals.
Chief Customer Success Officer, Aizon
CPV-enabled Refinement of Biotechnological Manufacturing Recipe
Although manufacturers can use in- line and on-line sensors to directly measure Critical Process Parameter (CPP) variability, this will only help to identify an out-of-control process that risks entire batch rejection upon reaching out-of-specification (OOS) conditions. A subsequent major challenge is how to leverage such information to directly interact with a pre-approved recipe, and maintain a state of control while driving process deviations within established conditions (ECs) for successful drug manufacturing according to GxP guidelines.
In this context, Aizon is leading the “CPV of the Future” project to answer questions such as how to apply advanced analytics and artificial intelligence (AI) to support decision-making and maintain regulatory compliance.
CSO at Aizon
Global Biotech Company Reduces Risk in Downstream Purification
Their goal was to figure out how to choose the best selection of available bags in inventory that, across 6 runs, would provide the optimal total yield of protein, without risk of sacrificing the yield of later runs by using the ‘best bags’ in the early runs of a campaign. How could they pool selection of bags in each run, and 1) fulfill the ‘hard requirements’ per the control strategy (e.g. total start protein concentration, harvest day distribution, etc.) and 2) optimize to predicted yield per run and in aggregate for the campaign?
Global Biotech Company
Multinational Biopharmaceutical Company Reduces Number of Downstream Ultrafiltration Recirculations via Predictive Analytics
Leveraging an accurate prediction model, this biopharmaceutical company has now proven the ability to go from multiple recirculations to getting the ultrafiltration process step “Right First Time.” Recirculations are now no longer necessary and they estimated a 61% reduction in the total number of runs and a 53% boost in process effectiveness. Moving forward, they now have all of the data they need for a good AI approach. The data is no longer lost and it is all captured in a GxP-compliant manner making any future audits easier, too.
Multinational Biopharmaceutical Company